Sunday, July 6, 2025 7/6/2025

Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers

Award Number: U01DE028227
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/19/2018
PERIOD OF PERFORMANCE END DATE: 08/31/2024

Group Awards By:

View Award Description

Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers - Abstract Neoantigens (NeoAg) offer a unique and powerful opportunity for directing a patient’s immune response specifically to cancer cells while avoiding damage to normal tissues. Methods for their reliable identification in tumors of moderate mutational burden such as head and neck squamous cell carcinoma (HNSCC) are lacking, however, as are preclinical experimental platforms for utilizing human material to understand the possibilities and impediments in enabling NeoAg-specific T cells to eradicate established tumors. Working with a focused and collaborative team with expertise in cellular and molecular immunology, bioinformatics, and translational oncology, we have developed a set of novel tools and approaches to address the complex tumor/immune ecosystem in new and incisive ways. These include a unique new model of tobacco-induced HNSCC carcinogenesis which recapitulates many key features of the human disease including gene expression patterns of activated oncogenes, a powerful new combined bioinformatic and functional analysis platform the identification of NeoAg by these tumors can be recognized by the host immune system, a novel preclinical model of combination radio-immunotherapy through which NeoAg-specific responses can be induced and sustained (Sharabi/Sharma), and finally, a new preclinical model of tumor-induced unresponsiveness in the setting of adoptive cellular therapy using human HNSCC patient-derived xenograft (PDX) tumors and patient-matched tumor-infiltrating lymphocytes (TIL) specific for an identified NeoAg. Together, these studies will address the hypothesis that autologous NeoAg-specific T cells can eradicate HNSCC tumors as well as defining the key quantitative and qualitative parameters governing therapeutic efficacy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	5	4/7/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	5	1/3/2023	NON-COMPETING CONTINUATION	$0
2023	2020	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	3	12/6/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $838,091 )
2022	2022	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	5	8/15/2022	NON-COMPETING CONTINUATION	$838,091
2022	2020	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	2	9/29/2022	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $838,091

Issue Date FY: 2021 ( Subtotal = $849,319 )
2021	2021	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	4	8/2/2021	NON-COMPETING CONTINUATION	$849,319
2021	2021	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	4	9/10/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $849,319

Issue Date FY: 2020 ( Subtotal = $1,193,143 )
2020	2020	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	004	2	9/23/2020	SUPPLEMENT FOR EXPANSION	$0
2020	2020	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	002	3	8/12/2020	NON-COMPETING CONTINUATION	$827,143
2020	2020	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	003	2	8/12/2020	SUPPLEMENT FOR EXPANSION	$0
2020	2020	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	2	4/15/2020	SUPPLEMENT FOR EXPANSION	$366,000
2020	2019	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	2	11/6/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,193,143

Issue Date FY: 2019 ( Subtotal = $852,739 )
2019	2019	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	2	7/31/2019	NON-COMPETING CONTINUATION	$852,739
														Subtotal = $852,739

Issue Date FY: 2018 ( Subtotal = $879,388 )
2018	2018	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	9/18/2018	NEW	$879,388
														Subtotal = $879,388

Grand Total All Awards = $4,612,680

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers

Award Number: U01DE028227

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/19/2018

PERIOD OF PERFORMANCE END DATE: 08/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer